Extended Data Fig. 9: WNTinib outperforms clinical compounds across in vivo models of HCC.
a-b, Dose escalation of WNTinib in BALB/c mice (a) and BALB/c/nude mice (b). Animals were dosed every day via oral gavage for 2 weeks. Percentage change in body weight noted in brackets (N = 3 animals per group; mean, SEM). c. Histological images (H&E) of liver, small & large intestine, and kidney from BALB/c mice treated with WNTinib at either 60 mg/kg or 120 mg/kg via oral gavage for 14 days. d, Images of C57BL/6 J mice treated with either vehicle or WNTinib for extended periods of time. WNTinib-treated animals present mosaic patterns of grey hair. e, Quantitative PCR expression of apoptotic genes in tumors derived from mice in panel Fig. 7e (N = 3 per group). *** P < .0005, as calculated with two-tailed paired t-tests. Exact P values listed in source data. For panel c, representative images are shown (n = 3). Extended data associated with Fig. 8.
